Physicochemical properties and release of the active ingredient from the dosage form are influenced by the methods of preparation of the dosage forms, the process conditions, and the addition of the various excipients. Embedding of the active pharmaceutical ingredient into a new dosage form can significantly contribute to its efficiency, safety, dosage suitability, and reduction of the side effects. Research involves the preparation of four dosage forms of the active pharmaceutical ingredient, dronedarone hydrochloride, used as a drug for cardiac arrhythmias. Dosage forms are prepared by pelletization, microencapsulation and 3D printing. The pellets were prepared by extrusion/spheronization process. DNR is loaded into the porous pellets in the form of the drug suspension by vacuum impregnation and direct loading in the extrusion process. The prepared pellets were coated with hydroxypropyl methylcellulose in a fluidized bed. The microcapsules were prepared in a laboratory spray dryer at four different atomization air flowrates. Solutions of DNR and poly (vinyl alcohol) and DNR and methacrylate copolymers were prepared in different weight ratios of 1:1, 1:2 and 1:3. The morphology of the prepared microcapsules was examined by scanning electron microscope. Poly (vinyl alcohol) filaments were used for 3D printing of the capsules with different wall thicknesses (0.25 mm, 0.50 mm, 0.75 mm and 1 mm), by the fused deposition modeling. The capsule comprises two caps and an inner part. The quality of 3D-printed capsules was examined using a scanning electron microscope and stereomicroscope. In order to successfully 3D print the tablet, the active ingredient DNR is loaded into the PVA filament. Hot melt extrusion at 170 °C was used to prepare the filaments. The optimal mass fraction process of the DNR loading and the influence of two different plasticizers on filament quality were investigated. The obtained filaments were used for 3D printing of tablets with different infill densities. Thermal characterization of the materials and filaments was performed, DNR content in filaments was determined and morphology of filaments and tablets was checked. All dosage forms were tested for in vitro DNR release and stability. Release kinetics was described, while in vitro – in vivo correlations were used to predict the in vivo behavior of prepared dosage forms. The results showed that loading technique of the DNR into the pellets and filaments, atomization air flowrates and the ratio of the DNR to polymer in the microcapsules, the various wall thickness of the 3D printed capsules and infill density of the 3D printed tablets have a significant influence on the release of DNR from dosage forms. The description of the released kinetics indicates the rate and mechanism of drug release. In vitro – in vivo correlations showed good agreement of the pharmacokinetic parameters obtained by simulation and convolution for samples of pellet, 3D-printed capsules with a wall thickness of 0.50 mm and microcapsules of methacrylate copolymer.